Daiichi Sankyo, with new data, to seek FDA approval of lung cancer drug
BioPharma Drive: Drug Pricing
SEPTEMBER 11, 2023
The HER3-targeting treatment could become the next antibody-drug conjugate to emerge from Daiichi Sankyo’s laboratories, after the AstraZeneca-partnered Enhertu.
Let's personalize your content